AU2012249601A1 - Compositions and method for treating autoimmune diseases - Google Patents

Compositions and method for treating autoimmune diseases Download PDF

Info

Publication number
AU2012249601A1
AU2012249601A1 AU2012249601A AU2012249601A AU2012249601A1 AU 2012249601 A1 AU2012249601 A1 AU 2012249601A1 AU 2012249601 A AU2012249601 A AU 2012249601A AU 2012249601 A AU2012249601 A AU 2012249601A AU 2012249601 A1 AU2012249601 A1 AU 2012249601A1
Authority
AU
Australia
Prior art keywords
interferon
patient
antibody
ism
lupus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012249601A
Other languages
English (en)
Inventor
Richard Boismenu
Jorn DRAPPA
William D. Kennedy
Romeo MACIUCA
Jacqueline MCBRIDE
Alyssa M. Morimoto
Michael J. Townsend
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to AU2013204880A priority Critical patent/AU2013204880B2/en
Priority to AU2013204776A priority patent/AU2013204776A1/en
Publication of AU2012249601A1 publication Critical patent/AU2012249601A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
AU2012249601A 2011-04-26 2012-04-26 Compositions and method for treating autoimmune diseases Abandoned AU2012249601A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2013204880A AU2013204880B2 (en) 2011-04-26 2013-04-12 Compositions and method for treating autoimmune diseases
AU2013204776A AU2013204776A1 (en) 2011-04-26 2013-04-12 Compositions and method for treating autoimmune diseases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161479314P 2011-04-26 2011-04-26
US61/479,314 2011-04-26
US201161582179P 2011-12-30 2011-12-30
US61/582,179 2011-12-30
PCT/US2012/035313 WO2012149228A1 (en) 2011-04-26 2012-04-26 Compositions and method for treating autoimmune diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2013204880A Division AU2013204880B2 (en) 2011-04-26 2013-04-12 Compositions and method for treating autoimmune diseases
AU2013204776A Division AU2013204776A1 (en) 2011-04-26 2013-04-12 Compositions and method for treating autoimmune diseases

Publications (1)

Publication Number Publication Date
AU2012249601A1 true AU2012249601A1 (en) 2013-05-09

Family

ID=47072761

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012249601A Abandoned AU2012249601A1 (en) 2011-04-26 2012-04-26 Compositions and method for treating autoimmune diseases

Country Status (8)

Country Link
US (1) US20140056889A1 (enExample)
EP (1) EP2701742A4 (enExample)
JP (1) JP6211513B2 (enExample)
KR (1) KR20140048877A (enExample)
AR (1) AR086074A1 (enExample)
AU (1) AU2012249601A1 (enExample)
CA (1) CA2834203A1 (enExample)
WO (1) WO2012149228A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101473045B (zh) 2006-04-24 2016-08-03 健泰科生物技术公司 用于检测自身免疫性病症的方法和组合物
RU2013157177A (ru) * 2011-05-25 2015-06-27 МЕДИММЬЮН, ЭлЭлСи Способы лечения системной красной волчанки, склеродермии и миозита
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
GB201501613D0 (en) * 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
JP6979976B2 (ja) 2016-03-10 2021-12-15 ヴィエラ バイオ，インコーポレーテッド Ｉｌｔ７結合分子及びその使用方法
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018136625A2 (en) * 2017-01-20 2018-07-26 Children's Medical Center Corporation Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss
US12486320B1 (en) * 2018-01-15 2025-12-02 Washington University Compositions and methods for treatment of central nervous system (CNS) autoimmune associated diseases or disorders
US11769592B1 (en) 2018-10-07 2023-09-26 Cerner Innovation, Inc. Classifier apparatus with decision support tool
US11749404B1 (en) * 2018-10-08 2023-09-05 Cerner Innovation, Inc. Decision support tool for venous thromboembolism (VTE)
CA3117102A1 (en) * 2018-10-26 2020-04-30 Janssen Biotech, Inc. Type i interferon signatures and methods of use
KR102308865B1 (ko) * 2019-02-08 2021-10-05 서울대학교산학협력단 전신 홍반 루푸스 산모의 임신 위험도를 평가하는 방법
JP7494416B2 (ja) * 2019-10-31 2024-06-04 義知 本田 血管老化予測方法、疾患リスク予測方法、血管老化予測用バイオマーカー、疾患用バイオマーカー、測定キット、及び、診断装置
IL293572A (en) * 2019-12-06 2022-08-01 Viela Bio Inc Treatment methods using ilt7 binding proteins
WO2021203013A2 (en) 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
CN114836534A (zh) * 2021-06-08 2022-08-02 中国医学科学院北京协和医院 Samd9l基因突变作为i型干扰素病诊断的标志物及其应用
AU2024266667A1 (en) * 2023-05-02 2025-10-30 4E Therapeutics, Inc. Composition, methods and uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
EP1851248B1 (en) * 2005-02-10 2016-08-10 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CN101473045B (zh) * 2006-04-24 2016-08-03 健泰科生物技术公司 用于检测自身免疫性病症的方法和组合物
WO2008070135A2 (en) * 2006-12-06 2008-06-12 Medimmune, Llc. Methods of treating systemic lupus erythematosus
WO2008137838A2 (en) * 2007-05-03 2008-11-13 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
PE20120359A1 (es) * 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
SMT201700063T1 (it) * 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases

Also Published As

Publication number Publication date
EP2701742A1 (en) 2014-03-05
AR086074A1 (es) 2013-11-13
US20140056889A1 (en) 2014-02-27
CA2834203A1 (en) 2012-11-01
EP2701742A4 (en) 2015-03-18
JP6211513B2 (ja) 2017-10-11
WO2012149228A1 (en) 2012-11-01
JP2014519487A (ja) 2014-08-14
KR20140048877A (ko) 2014-04-24

Similar Documents

Publication Publication Date Title
US20140056889A1 (en) Compositions and method for treating autoimmune diseases
TWI656217B (zh) 用於治療補體相關病況之組合物及方法
US20070014797A1 (en) Method for treating Sjogren's syndrome
KR102148063B1 (ko) 베타7 인테그린 길항제를 투여하는 방법
US20070218062A1 (en) Methods of treating lupus using CD4 antibodies
US20160178644A1 (en) Methods for diagnosing and treating inflammatory bowel disease
US20060110387A1 (en) Method for treating vasculitis
WO2013101771A2 (en) Compositions and method for treating autoimmune diseases
JP2010527325A (ja) Ｂ細胞アンタゴニストに応答する関節リウマチを予測するバイオマーカー
KR20080105025A (ko) 관절 손상의 치료 방법
JP2018064566A6 (ja) 補体関連病態を治療するための組成物及び方法
KR20070122543A (ko) 항-ｃｄ20 항체에 의한 염증성 장 질환 (ｉｂｄ)의 치료방법
BR112020026384A2 (pt) Métodos para tratar um indivíduo com câncer de pulmão e para tratar um indivíduo com câncer de pulmão de pequenas células, kits, anticorpo anti-pd-l1 e composição
US20230391875A1 (en) Diagnostic and therapeutic methods for cancer
US20080279848A1 (en) Methods of treating lupus using CD4 antibodies
AU2013204880B2 (en) Compositions and method for treating autoimmune diseases
JP2025523387A (ja) 抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
MX2007003857A (en) Method for treating vasculitis
HK1239758A1 (en) Compositions and method for treating compliment-associated conditions

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted